A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Prior systemic anticancer treatment including investigational agents within 3 weeks (or 5 half-lives, whichever is shorter) before the first dose of study treatment
• •Major surgery planned or within 5 weeks before the first dose of study treatment, or minor surgical procedure (except tumor biopsy) within 7 days before the first dose of study treatment.
• •Radiotherapy within 2 weeks before the first dose of study treatment.
• •Evidence of severe active or chronic infections requiring systemic antibacterial, antiviral, or antifungal treatment, including tuberculosis infection
• •Known seropositivity for or active infection with human immunodeficiency virus (HIV)
• •Known seropositivity for hepatitis B virus (HBV), with evidence of active HBV infection
• •Known seropositivity for hepatitis C virus (HCV), with evidence of active HCV infection
• •Live or live-attenuated vaccine within 30 days before the first dose of study treatment.
• •History or current evidence of uncontrolled or significant cardiovascular disease
• •History or current evidence of significant autoimmune disease that required systemic
• •treatment
• •Diagnosis of immunodeficiency or any condition requiring systemic treatment with immunosuppressive medication
• •Pregnant or breastfeeding.